{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:06:34Z","timestamp":1780308394098,"version":"3.54.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2025.102868","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:27:36Z","timestamp":1765931256000},"page":"102868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reassessing the risks: toxicity of stereotactic ablative radiotherapy after bevacizumab in oligometastatic ovarian cancer\u2014a new perspective for radiation oncologists?"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1169","authenticated-orcid":false,"given":"Donato","family":"Pezzulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-5232","authenticated-orcid":false,"given":"Maura","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4370-8271","authenticated-orcid":false,"given":"Raffaella","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6046-3359","authenticated-orcid":false,"given":"Simona","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-4390","authenticated-orcid":false,"given":"Andrei","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Balcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8308-929X","authenticated-orcid":false,"given":"Francesca","family":"Titone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Roberto","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Draghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Giaccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tortoreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-5070","authenticated-orcid":false,"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-201X","authenticated-orcid":false,"given":"Gabriella","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijgc.2025.102868_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10.1016\/j.ijgc.2025.102868_bib3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol."},{"issue":"26","key":"10.1016\/j.ijgc.2025.102868_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102868_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.102868_bib6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102868_bib7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102868_bib9","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102868_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102868_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ijgc.2025.102868_bib12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102868_bib13","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102868_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae insights: ovarian cancer\/Fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102868_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102868_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102868_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","article-title":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","volume":"189","author":"Kamrava","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102868_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijrobp.2024.09.010","article-title":"Stereotactic body radiation therapy for Oligoprogressive ovarian cancer patients treated during poly(ADP-ribose)-polymerase inhibitor maintenance: efficacy and adverse events from the Epimetheo retrospective study","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"8","key":"10.1016\/j.ijgc.2025.102868_bib19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102868_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102868_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3\/RAD Phase II trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2025.03.032","article-title":"Treatment of oligometastatic parenchymal lesions in ovarian cancer with stereotactic ablative radiation therapy: a multicenter prospective Phase 2 trial (MITO RT3\/RAD)","volume":"123","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102868_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102868_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0360-3016(01)01495-X","article-title":"Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA)","volume":"50","author":"Salazar","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102868_bib26","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.ijgc.2025.102868_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phro.2018.01.001","article-title":"Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy","volume":"5","author":"Detsky","year":"2018","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102868_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/1754-9485.12489","article-title":"Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: the Dunedin Hospital experience","volume":"60","author":"Haji","year":"2016","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ijgc.2025.102868_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.critrevonc.2018.11.006","article-title":"Combination of novel systemic agents and radiotherapy for solid tumors - part II: an AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity","volume":"134","author":"Arcangeli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102868_bib31","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2011.38.4552","article-title":"Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer","volume":"30","author":"Lind","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13014-024-02458-x","article-title":"The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy","volume":"19","author":"Chen","year":"2024","journal-title":"Radiat Oncol"},{"issue":"10103","key":"10.1016\/j.ijgc.2025.102868_bib33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102868_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ijgc-2020-002031","article-title":"Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer","volume":"31","author":"Kim","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102868_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 Consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:34:04Z","timestamp":1780306444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X25019929"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102868","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the risks: toxicity of stereotactic ablative radiotherapy after bevacizumab in oligometastatic ovarian cancer\u2014a new perspective for radiation oncologists?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102868"}}